Evidence map›Paper›PMID 37638430›Full record

ArticleJournal of Alzheimer's disease : JAD2023

Psychological Status of the Participants in Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia.

Claudia Ramos, Claudia Madrigal, Daniel Camilo Aguirre-Acevedo, Margarita Giraldo-Chica, Natalia Acosta-Baena, Claudia Aponte, David Aguillón, Manuela Gómez, Alejandro Espinosa, Lucia Madrigal and 12 more

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Claudia RamosNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Claudia MadrigalNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Daniel Camilo Aguirre-AcevedoNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Margarita Giraldo-ChicaNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Natalia Acosta-BaenaNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Claudia AponteNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
David AguillónNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Manuela GómezNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Alejandro EspinosaNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Lucia MadrigalNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Claramonika UribeNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Amanda SaldarriagaNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Diana AlzateNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Alejandra RuizNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Angela AndradeNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Hugo LopezNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Jessica B LangbaumBanner Alzheimer's Institute, Phoenix, AZ, USA.
Kaycee M SinkGenentech Inc., South San Francisco, CA, USA.
Eric M ReimanBanner Alzheimer's Institute, Phoenix, AZ, USA.
Pierre N TariotBanner Alzheimer's Institute, Phoenix, AZ, USA.
Silvia Ríos-RomenetsNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.
Francisco LoperaNeuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia.

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
API A4 Alzheimer's Prevention TrialR01AG058468 · NIA · BANNER HEALTH · PI AISEN, PAUL S., ALEXANDER, ROBERT C · 2018 to 2025
$31.9M
APOE in the Predisposition to, Protection from and Prevention of Alzheimer's DiseaseR01AG069453 · NIA · BANNER HEALTH · PI ASHTON, NICHOLAS, LANGBAUM, JESSICA BROOKE · 2020 to 2025
$27.4M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9M
Alzheimer's Prevention InitiativeRF1AG041705 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2012 to 2012
$15.3M
Alzheimer's Prevention Initiative ADAD Colombia TrialR01AG055444 · NIA · BANNER HEALTH · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2017 to 2022
$14.9M
Establishing the science behind Alzheimer's recruitment registries: opportunities for increasing diversity and accelerating enrollment into trialsR01AG063954 · NIA · BANNER HEALTH · PI BLEAKLEY, AMY, LANGBAUM, JESSICA BROOKE · 2019 to 2023
$9.6M
Optimizing Research Infrastructure of Registries to Accelerate Participant Recruitment into Alzheimer's Focused StudiesR33AG070604 · NIA · BANNER HEALTH · PI LANGBAUM, JESSICA BROOKE · 2021 to 2025
$3.9M
NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG055444NIA NIH HHS R01 AG058468NIA NIH HHS R01 AG063954NIA NIH HHS R01 AG069453NIA NIH HHS R33 AG070604NIA NIH HHS RF1 AG041705
6 · The paper itself

Abstract

backgroundThe SARS-CoV2 global pandemic impacted participants in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) clinical trial, who faced three stressors: 1) fear of developing dementia; 2) concerns about missing treatment; and 3) risk of SARS-CoV2 infection.

objectiveTo describe the frequency of psychological disorders among the participants of the API ADAD Colombia clinical study, treated by a holistic mental health team during the COVID-19 pandemic. The extent of use of mental health team services was explored considering different risk factors, and users and non-users of these services were compared.

methodsParticipants had free and optional access to psychology and psychiatry services, outside of the study protocol. Descriptive statistics was used to analyze the frequency of the mental health difficulties. A multivariable logistic regression model has been used to assess associations with using this program.

results66 participants were treated by the Mental Health Team from March 1, 2020, to December 31, 2020. Before and after the start of the pandemic, the most common psychological problems were anxiety (36.4% before, 63.6% after) and depression (34.8% before, 37.9% after). 70% of users assisted by psychology and 81.6% of those assisted by psychiatry felt that the services were useful for them. Female sex, depression, and anxiety before the pandemic were positively associated with being assisted by either psychology or psychiatry, while the association with hyperlipidemia was negative.

conclusionsA holistic mental health program, carried out in the context of a study, could mitigate psychopathology during pandemics such as COVID-19.

Indexed as

Alzheimer DiseaseCOVID-19AnxietyColombiaDepressionFemaleHumansPandemicsRNA, ViralSARS-CoV-2RNA, ViralAlzheimer’s diseaseCOVID-19health services and institutions

Identifiers

PMID37638430
PMCPMC10715735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.